Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023GlobeNewsWire • 08/04/23
Iterum Therapeutics Presents Scientific Posters at ECCMID 2023 Highlighting Application of Desirability of Outcomes Ranking (DOOR) to two Registration TrialsGlobeNewsWire • 04/20/23
All You Need to Know About Iterum Therapeutics PLC (ITRM) Rating Upgrade to Strong BuyZacks Investment Research • 04/13/23
Iterum Therapeutics Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 03/16/23
Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023GlobeNewsWire • 03/09/23
Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral SulopenemGlobeNewsWire • 12/15/22
Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionsGlobeNewsWire • 10/20/22
Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/07/22
Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDAGlobeNewsWire • 07/11/22
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 07/06/22